Browse > Article
http://dx.doi.org/10.4070/kcj.2012.42.6.371

Linkage of Epidemiologic Evidence With the Clinical Aspects of Metabolic Syndrome  

Jee, Sun-Ha (Institute for Health Promotion, Department of Epidemiology and Health Promotion, Graduate School of Public Health, Yonsei University)
Jo, Jae-Seong (Department of Public Health, Graduate School, Yonsei University)
Publication Information
Korean Circulation Journal / v.42, no.6, 2012 , pp. 371-378 More about this Journal
Abstract
Metabolic syndrome (MetS) is characterized by a cluster of cardiovascular risk factors, such as hypertension, glucose intolerance, high triglycerides, and a low high density lipoprotein-cholesterol level. MetS is known to be associated with cardiovascular diseases. In order to diagnose MetS, definitions such as National Cholesterol Education Program Adult Treatment Panel III, American Heart Association/National Heart Lung and Blood Institute, International Diabetes Federation, World Health Organization, European Group for the Study of Insulin Resistance and American College of Endocrinology are widely used. However, using different criteria may lead to confusion regarding the diagnosis and treatment of patients with MetS in the primary care setting. Our objected was to review 3 aspects concerning MetS using the Metabolic Syndrome Research Initiatives study of 123892 healthy Koreans (1994-2001) that had a maximum follow-up of 12 years. The 3 aspects were reviewed by determination of the association of MetS with the development of atherosclerotic cardiovascular disease (ASCVD) and ischemic heart disease (IHD). Based on our findings, each metabolic factor associated with MetS was not weighted equally. The hazard ratio (HR) was higher in individuals with higher glucose compared with the HR in individuals with higher body mass index. Individuals with pre-MetS (having 1 or 2 metabolic factors) had 1.5-2.3 fold higher risk of developing ASCVD and IHD in both genders. In the presence of MetS, both singly and in combination, precede the development of ASCVD and IHD and individuals with pre-MetS must not be ignored as there is no apparent threshold in defining MetS. Furthermore, MetS may complement the Framingham Risk Score and can be used as the first line approach to treat the ASCVD or IHD.
Keywords
Metabolic cardiovascular syndrome; Atherosclerosis; Ischemic heart disease;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-9.   DOI   ScienceOn
2 Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-16.   DOI   ScienceOn
3 Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005;112: 666-73.   DOI   ScienceOn
4 Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173: 309-14.
5 Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52: 1210-4.   DOI   ScienceOn
6 Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010;375:181-3.   DOI   ScienceOn
7 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.   DOI   ScienceOn
8 Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.   DOI   ScienceOn
9 Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003;9:236-52.
10 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.   DOI   ScienceOn
11 De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003;24:1601-10.   DOI   ScienceOn
12 Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735-52.   DOI   ScienceOn
13 Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:e297-8.   DOI
14 Meigs JB. Metabolic syndrome: in search of a clinical role. Diabetes Care 2004;27:2761-3.   DOI   ScienceOn
15 Kahn R, Buse J, Ferrannini E, Stern M; American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.   DOI   ScienceOn
16 Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-81.   DOI   ScienceOn
17 Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2005;28:238.   DOI
18 Meigs JB. Metabolic syndrome: in search of a clinical role. Diabetes Care 2005;28:238.
19 Kimm H, Yun JE, Jo J, Jee SH. Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009;40:3422-7.   DOI   ScienceOn
20 Kim HC, Kang DR, Nam CM, et al. Elevated serum aminotransferase level as a predictor of intracerebral hemorrhage: Korea Medical Insurance Corporation Study. Stroke 2005;36:1642-7.   DOI   ScienceOn
21 Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. N Eng J Med 2006;355:779-87.   DOI   ScienceOn
22 World Health Organization. International Classification of Diseases and Related Health Problems: Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death. 10th ed. Geneva: World Health Organization;1992.
23 Park JK, Kim KS, Kim CB, et al. The accuracy of ICD codes for cerebrovascular diseases in medical insurance claims. Korean J Prev Med 2000;33:76-82.
24 Inoue S, Zimmet P, Caterson I, et al. The Asia-Pacific Perspective: Redefining Obesity and its Treatments: International Obesity Task Force. Western Pacific Region of the World Health Organization, Sydney: Health commuication; 2000.
25 Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002;106:1930-7.   DOI   ScienceOn
26 Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004;109:433-8.   DOI   ScienceOn
27 Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004;109:551-6.   DOI   ScienceOn
28 Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-600.   DOI   ScienceOn
29 Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002;1:1.   DOI
30 Haffner SM. Cardiovascular risk factors and the prediabetic syndrome. Ann Med 1996;28:363-70.
31 Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition: a Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
32 Katzmarzyk PT, Janssen I, Ross R, Church TS, Blair SN. The importance of waist circumference in the definition of metabolic syndrome: prospective analyses of mortality in men. Diabetes Care 2006;29:404-9.   DOI   ScienceOn
33 Yoon YS, Lee ES, Park C, Lee S, Oh SW. The new definition of metabolic syndrome by the international diabetes federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised national cholesterol education program: the Korea NHANES Study. Int J Obes (Lond) 2007;31:528-34.   DOI   ScienceOn
34 World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation: Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization;1999.
35 American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012;35(Suppl 1):S64-71.   DOI
36 Kadota A, Hozawa A, Okamura T, et al. Relationship between metabolic risk factor clustering and cardiovascular mortality stratified by high blood glucose and obesity: NIPPON DATA90, 1990-2000. Diabetes Care 2007;30:1533-8.   DOI   ScienceOn
37 Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005;28:1769-78.   DOI   ScienceOn
38 Anderson JL, Horne BD, Jones HU, et al. Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease? Cardiology 2004;101:185-93.   DOI   ScienceOn
39 Andreadis EA, Tsourous GI, Tzavara CK, et al. Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population. Am J Hypertens 2007;20:558-64.   DOI   ScienceOn
40 Nakanishi N, Takatorige T, Fukuda H, et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 2004; 64:59-70.   DOI   ScienceOn
41 D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.   DOI   ScienceOn
42 Jaquet A, Deloumeaux J, Dumoulin M, Bangou J, Donnet JP, Foucan L. Metabolic syndrome and Framingham risk score for prediction of cardiovascular events in Caribbean Indian patients with blood glucose abnormalities. Diabetes Metab 2008;34:177-81.   DOI   ScienceOn
43 McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-90.   DOI   ScienceOn
44 Wannamethee SG, Shaper AG, Lennon L, Morris RW. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 2005;165: 2644-50.   DOI   ScienceOn